Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neurofibromatosis Type II”

109 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 109 results

Testing effectiveness (Phase 2)Looking for participantsNCT04750928
What this trial is testing

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Who this might be right for
Neurofibromatosis 1
National Cancer Institute (NCI) 55
Very early researchStudy completedNCT00863122
What this trial is testing

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Who this might be right for
Vestibular SchwannomaNF2Neurofibromatosis 2+2 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT02407405
What this trial is testing

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis 1 (NF1)Plexiform Neurofibromas (PN)
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131722
What this trial is testing

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

Who this might be right for
Neurofibromatosis Type IINF2
PRG Science & Technology Co., Ltd. 25
Testing effectiveness (Phase 2)Study completedNCT00030264
What this trial is testing

Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis Type 1Precancerous Condition
Children's Hospital of Philadelphia 23
Not applicableLooking for participantsNCT00598351
What this trial is testing

Natural History Study of Patients With Neurofibromatosis Type 2

Who this might be right for
Neurofibromatosis
National Institute of Neurological Disorders and Stroke (NINDS) 269
Post-approval studies (Phase 4)WithdrawnNCT00588172
What this trial is testing

Genetic Variation in OCT1 and Response to Metformin

Who this might be right for
Type 2 Diabetes
Mayo Clinic
Testing effectiveness (Phase 2)Study completedNCT03326388
What this trial is testing

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

Who this might be right for
Neurofibromatosis Type 1Plexiform NeurofibromaOptic Nerve Glioma
Great Ormond Street Hospital for Children NHS Foundation Trust 14
Testing effectiveness (Phase 2)Study completedNCT01673009
What this trial is testing

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis
Indiana University 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT04954001
What this trial is testing

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Who this might be right for
Neurofibromatosis 1Plexiform NeurofibromaNF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 160
Testing effectiveness (Phase 2)Study completedNCT04283669
What this trial is testing

Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Who this might be right for
Neurofibromatosis 2Progressive Vestibular Schwannoma (VS)
University of Alabama at Birmingham 12
Testing effectiveness (Phase 2)Ended earlyNCT02315625
What this trial is testing

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more
National Cancer Institute (NCI) 16
Not applicableUnknownNCT05685836
What this trial is testing

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Who this might be right for
Neurofibromatosis 2
Leiden University Medical Center 15
Testing effectiveness (Phase 2)Study completedNCT00754780
What this trial is testing

Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1

Who this might be right for
Neurofibromatosis
Mayo Clinic 24
Not applicableEnded earlyNCT01736267
What this trial is testing

Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects

Who this might be right for
Bilateral Hearing Loss for Causes Other Than Tumors
Massachusetts Eye and Ear Infirmary 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06621082
What this trial is testing

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

Who this might be right for
Neurofibromatosis 1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03079999
What this trial is testing

Study of Aspirin in Patients With Vestibular Schwannoma

Who this might be right for
Vestibular SchwannomaAcoustic NeuromaNeurofibromatosis 2
Massachusetts Eye and Ear Infirmary 97
Not applicableLooking for participantsNCT03050268
What this trial is testing

Familial Investigations of Childhood Cancer Predisposition

Who this might be right for
Acute LeukemiaAdenomatous PolyposisAdrenocortical Carcinoma+43 more
St. Jude Children's Research Hospital 1,500
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439318
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT01089101
What this trial is testing

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Who this might be right for
Low Grade GliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Neurofibromatosis Type 1+3 more
National Cancer Institute (NCI) 217
Load More Results